Inovio Pharmaceuticals (NASDAQ:INO) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.23, Zacks reports.

Inovio Pharmaceuticals Stock Down 1.2 %

Inovio Pharmaceuticals stock traded down $0.03 during mid-day trading on Tuesday, hitting $2.09. 500,586 shares of the stock were exchanged, compared to its average volume of 539,743. The stock has a market capitalization of $54.42 million, a price-to-earnings ratio of -0.99 and a beta of 0.92. The firm’s fifty day simple moving average is $2.05 and its two-hundred day simple moving average is $3.81. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Oppenheimer reduced their target price on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, HC Wainwright decreased their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.40.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.